发布求助
文献互助 智能选刊 最新文献

Pharmacogenomics最新文献

筛选
英文 中文
Pharmacogenomic markers associated with drug-induced QT prolongation: a systematic review. 与药物性QT间期延长相关的药物基因组学标志物：一项系统综述。
IF 1.9 4区 医学
Pharmacogenomics Pub Date : 2025-01-01 Epub Date: 2025-03-21 DOI: 10.1080/14622416.2025.2481025
Marlene Schouby Bentestuen, Christian Noe Weis, Caroline Bækmann Jeppesen, Liv Swea Thiele, Janne Pia Thirstrup, Juan Cordero-Solorzano, Henrik Kjærulf Jensen, Anna Starnawska, Alexander Sebastian Hauser, Christiane Gasse
{"title":"Pharmacogenomic markers associated with drug-induced QT prolongation: a systematic review.","authors":"Marlene Schouby Bentestuen, Christian Noe Weis, Caroline Bækmann Jeppesen, Liv Swea Thiele, Janne Pia Thirstrup, Juan Cordero-Solorzano, Henrik Kjærulf Jensen, Anna Starnawska, Alexander Sebastian Hauser, Christiane Gasse","doi":"10.1080/14622416.2025.2481025","DOIUrl":"10.1080/14622416.2025.2481025","url":null,"abstract":"<p><strong>Aim: </strong>To systematically assess clinical studies involving patients undergoing drug therapy, comparing different genotypes to assess the relationship with changes in QT intervals, with no limitations on study design, setting, population, dosing regimens, or duration.</p><p><strong>Methods: </strong>This systematic review followed PRISMA guidelines and a pre-registered protocol. Clinical human studies on PGx markers of diQTP were identified, assessed using standardized tools, and categorized by design. Gene associations were classified as pharmacokinetic or pharmacodynamic. Identified genes underwent pathway enrichment analyses. Drugs were classified by third-level Anatomical Therapeutic Chemical (ATC) codes. Descriptive statistics were computed by study category and drug classes.</p><p><strong>Results: </strong>Of 4,493 reports, 84 studies were included, identifying 213 unique variants across 42 drug classes, of which 10% were replicated. KCNE1-Asp85Asn was the most consistent variant. Most findings (82%) were derived from candidate gene studies, suggesting bias toward known markers. The diQTP-associated genes were mainly linked to \"cardiac conduction\" and \"muscle contraction\" pathways (false discovery rate = 4.71 × 10<sup>-14</sup>). We also found an overlap between diQTP-associated genes and congenital long QT syndrome genes.</p><p><strong>Conclusion: </strong>Key genes, drugs, and pathways were identified, but few consistent PGx markers emerged. Extensive, unbiased studies with diverse populations are crucial to advancing the field.</p><p><strong>Registration: </strong>A protocol was pre-registered at PROSPERO under registration number CRD42022296097.</p><p><strong>Data deposition: </strong>Data sets generated by this review are available at figshare: DOI: 10.6084/m9.figshare.27959616.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":" ","pages":"53-72"},"PeriodicalIF":1.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11988217/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143674408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of CYP2C19 polymorphism testing on the risk of stent thrombosis in patients with carotid artery stenting. CYP2C19多态性检测对颈动脉支架植入术患者支架血栓形成风险的影响
IF 1.9 4区 医学
Pharmacogenomics Pub Date : 2025-01-01 Epub Date: 2025-03-31 DOI: 10.1080/14622416.2025.2478810
Huai Wu Yuan, Xia Huang, Min Ying Pan, Xuan Yu Chen, Yun Zhen Hu, Mei Hua Lin, Jian Er Wang, Yong Wu, Jun Hu, Mei Ling Cao, Hui Liang
{"title":"Impact of CYP2C19 polymorphism testing on the risk of stent thrombosis in patients with carotid artery stenting.","authors":"Huai Wu Yuan, Xia Huang, Min Ying Pan, Xuan Yu Chen, Yun Zhen Hu, Mei Hua Lin, Jian Er Wang, Yong Wu, Jun Hu, Mei Ling Cao, Hui Liang","doi":"10.1080/14622416.2025.2478810","DOIUrl":"10.1080/14622416.2025.2478810","url":null,"abstract":"<p><strong>Objective: </strong>We aimed to identify the impact of CYP2C19 polymorphism testing on clinical outcomes in patients who have undergone carotid artery stenting (CAS).</p><p><strong>Methods: </strong>This was a single-center retrospective cohort study. CYP2C19 polymorphisms were identified based on the presence of two normal functional alleles in normal metabolizers (NMs), a normal functional allele and a nonfunctional allele in intermediate metabolizers and two nonfunctional alleles in poor metabolizers. Patients were recommended for the CYP2C19 polymorphism testing followed by the change in dual antithrombotic drugs (DAPT) at the discretion of the supervising physician. The primary clinical endpoint was stent thrombosis (ST). Logistic regression was used to evaluate the relative risk of clinical outcomes.</p><p><strong>Results: </strong>A total of 273 patients were included. The relative risk of ST was not reduced in patients who underwent CYP2C19 polymorphism testing than in patients without this test (3.1% vs. 3.9%, OR = 0.914, 95% CI = 0.218-3.841). The ST in NMs and non-NMs was 3.4% and 2.9%, respectively, and showing no reduction in NMs (OR = 1.145, 95% CI = 0.162-8.105). Changing DAPT did not reduce the relative risk of ST compared with non-changing (2.3% vs. 3.2%, OR = 1.604, 95% CI = 0.024-107.033).</p><p><strong>Conclusions: </strong>CYP2C19 polymorphism was not related to stent thrombosis in patients with CAS.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":" ","pages":"31-37"},"PeriodicalIF":1.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11988242/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143754082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of CYP2D6 and ADRB1 polymorphisms on heart rate of post-PCI patients treated with metoprolol. CYP2D6和ADRB1多态性对接受美托洛尔治疗的PCI术后患者心率的影响
IF 2.1 4区 医学
Pharmacogenomics Pub Date : 2024-05-31 DOI: 10.2217/pgs-2017-0203
Xiaofeng Gao, Huan Wang, Hui Chen
{"title":"Impact of <i>CYP2D6</i> and <i>ADRB1</i> polymorphisms on heart rate of post-PCI patients treated with metoprolol.","authors":"Xiaofeng Gao, Huan Wang, Hui Chen","doi":"10.2217/pgs-2017-0203","DOIUrl":"10.2217/pgs-2017-0203","url":null,"abstract":"<p><p><b>Aim:</b> To explore the effect of <i>CYP2D6*10</i> (100C > T) and <i>ADRB1</i> 1165 G > C polymorphisms on heart rate of post-PCI (percutaneous coronary intervention) patients treated with metoprolol succinate sustained-release tablets. <b>Methods:</b> A total of 756 inpatients with metoprolol succinate sustained-release tablets were selected and the genotypes of <i>CYP2D6*10</i> and <i>ADRB1</i> 1165G > C were detected in 319 patients using gene chip detection. The target heart rate was defined as a resting heart rate < 70 beats/min. Clinical data were collected. <b>Results:</b> A total of 319 inpatients were enrolled in the study. The mutant allele frequencies of <i>CYP2D6</i> and <i>ADRB1</i> were 57.21 and 69.44%, respectively. Whatever the dose of metoprolol, the heart rates were lower in patients with homozygous mutation of <i>CYP2D6</i> than those with heterozygous mutation and wild-type (p < 0.05). Nevertheless, this effect was not seen between different genotypes of <i>ADRB1</i>. Logistic regression analysis showed that the dose of metoprolol and the genotypes of <i>CYP2D6</i> were predictors of heart rate <70 beats/min in these patients. Further multivariate analysis indicated that patients with homozygous mutation had better control of heart rates compared with those with wild-type and heterozygous mutation of <i>CYP2D6*10</i> genotypes (all: p < 0.001). <b>Conclusion:</b><i>CYP2D6*10</i> polymorphisms were associated with the heart rate of post-PCI patients treated with metoprolol succinate sustained-release tablets.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":" ","pages":"1-9"},"PeriodicalIF":2.1,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35515184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacogenomic implications of the differential distribution of CYP3A5 metabolic phenotypes among Latin American populations. 拉丁美洲人群中 CYP3A5 代谢表型不同分布的药物基因组学意义。
IF 2.1 4区 医学
Pharmacogenomics Pub Date : 2024-03-01 Epub Date: 2024-03-20 DOI: 10.2217/pgs-2024-0009
Guilherme Suarez-Kurtz, Claudio José Struchiner
{"title":"Pharmacogenomic implications of the differential distribution of CYP3A5 metabolic phenotypes among Latin American populations.","authors":"Guilherme Suarez-Kurtz, Claudio José Struchiner","doi":"10.2217/pgs-2024-0009","DOIUrl":"10.2217/pgs-2024-0009","url":null,"abstract":"<p><p>This study shows that the distribution of <i>CYP3A5</i> alleles (<i>*1</i>, <i>*3</i>, <i>*6</i> and <i>*7</i>) and genotype-predicted CYP3A5 phenotypes vary significantly across Latin American cohorts (Brazilians and the One Thousand Genomes Admixed American superpopulation), as well as among subcohorts comprising individuals with the highest proportions of Native, European or sub-Saharan African ancestry. Differences in biogeographical ancestry across the study groups are the likely explanation for these results. The differential distribution of CYP3A5 phenotypes has major pharmacogenomic implications, affecting the proportion of individuals carrying high risk CYP3A5 phenotypes for the immunosuppressant tacrolimus and the number of patients that would need to be genotyped to prevent acute rejection in kidney transplant recipients under tacrolimus treatment.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":" ","pages":"187-195"},"PeriodicalIF":2.1,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140175958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Knowledge and perceptions of pharmacogenomics among pharmacists in Manitoba, Canada. 加拿大马尼托巴省药剂师对药物基因组学的了解和看法。
IF 2.1 4区 医学
Pharmacogenomics Pub Date : 2024-03-01 Epub Date: 2024-03-20 DOI: 10.2217/pgs-2024-0013
Abdullah Al Maruf, Meagan Shields, Amber Fryza, Amanda Wondrasek, Christine Leong, Kaarina Kowalec, Chad Bousman
{"title":"Knowledge and perceptions of pharmacogenomics among pharmacists in Manitoba, Canada.","authors":"Abdullah Al Maruf, Meagan Shields, Amber Fryza, Amanda Wondrasek, Christine Leong, Kaarina Kowalec, Chad Bousman","doi":"10.2217/pgs-2024-0013","DOIUrl":"10.2217/pgs-2024-0013","url":null,"abstract":"<p><p><b>Objective:</b> This work was designed to describe the knowledge and perceptions of pharmacogenomics (PGx) among pharmacists in the Canadian province of Manitoba. <b>Methods:</b> A 40-item, web-based survey was distributed to pharmacists in Manitoba. <b>Results:</b> Of 74 participants, one third had some education or training in PGx, and 12.2% had used PGx test results in their practice. Participants' self-rated knowledge of PGx testing and common PGx resources (e.g., Pharmacogenomics Knowledge Base, Clinical Pharmacogenetics Implementation Consortium) was low. Most pharmacists surveyed believe that PGx can improve medication efficacy (82.4%) or prevent adverse drug reactions (81.1%). Most (91%) desired more education on PGx. <b>Conclusion:</b> Manitoba pharmacists reported positive perceptions toward PGx. However, they are currently underprepared to implement PGx into practice.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":" ","pages":"175-186"},"PeriodicalIF":2.1,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140175957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Implementation of whole-exome sequencing for pharmacogenomics profiling and exploring its potential clinical utilities. 采用全外显子组测序进行药物基因组学分析，探索其潜在的临床用途。
IF 2.1 4区 医学
Pharmacogenomics Pub Date : 2024-03-01 Epub Date: 2024-03-21 DOI: 10.2217/pgs-2023-0243
Danyi Wang, Jayaprakasam Bolleddula, Anna Coenen-Stass, Thomas Grombacher, Jennifer Q Dong, Juergen Scheuenpflug, Giuseppe Locatelli, Zheng Feng
{"title":"Implementation of whole-exome sequencing for pharmacogenomics profiling and exploring its potential clinical utilities.","authors":"Danyi Wang, Jayaprakasam Bolleddula, Anna Coenen-Stass, Thomas Grombacher, Jennifer Q Dong, Juergen Scheuenpflug, Giuseppe Locatelli, Zheng Feng","doi":"10.2217/pgs-2023-0243","DOIUrl":"10.2217/pgs-2023-0243","url":null,"abstract":"<p><p>Whole-exome sequencing (WES) is widely used in clinical settings; however, the exploration of its use in pharmacogenomic analysis remains limited. Our study compared the variant callings for 28 core absorption, distribution, metabolism and elimination genes by WES and array-based technology using clinical trials samples. The results revealed that WES had a positive predictive value of 0.71-0.92 and a sensitivity of single-nucleotide variants between 0.68 and 0.95, compared with array-based technology, for the variants in the commonly targeted regions of the WES and PhamacoScan™ assay. Besides the common variants detected by both assays, WES identified 200-300 exclusive variants per sample, totalling 55 annotated exclusive variants, including important modulators of metabolism such as rs2032582 (<i>ABCB1</i>) and rs72547527 (<i>SULT1A1</i>). This study highlights the potential clinical advantages of using WES to identify a wider range of genetic variations and enabling precision medicine.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":" ","pages":"197-206"},"PeriodicalIF":2.1,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140175956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacogenomics for Prader-Willi syndrome: caregiver interest and planned utilization. 普拉德-威利综合征的药物基因组学：护理人员的兴趣和计划利用。
IF 2.1 4区 医学
Pharmacogenomics Pub Date : 2024-03-01 Epub Date: 2024-03-20 DOI: 10.2217/pgs-2023-0189
Yael Bar-Peled, Jessica J Denton, Jaimie L Richards, Donna Brown, Elizabeth Worthey, Theresa V Strong
{"title":"Pharmacogenomics for Prader-Willi syndrome: caregiver interest and planned utilization.","authors":"Yael Bar-Peled, Jessica J Denton, Jaimie L Richards, Donna Brown, Elizabeth Worthey, Theresa V Strong","doi":"10.2217/pgs-2023-0189","DOIUrl":"10.2217/pgs-2023-0189","url":null,"abstract":"<p><p><b>Aim:</b> The study aim was to determine caregiver interest and planned utilization of pharmacogenomic (PGx) results for their child with Prader-Willi syndrome. <b>Methods:</b> Caregivers consented to PGx testing for their child and completed a survey before receiving results. <b>Results:</b> Of all caregivers (n = 48), 93.8% were highly interested in their child's upcoming PGx results. Most (97.9%) planned to share results with their child's medical providers. However, only 47.9% of caregivers were confident providers would utilize the PGx results. <b>Conclusion:</b> Caregivers are interested in utilizing PGx but are uncertain providers will use these results in their child's care. More information about provider comfort with PGx utilization is needed to understand how PGx education would benefit providers and ultimately patients with PGx results.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":" ","pages":"207-216"},"PeriodicalIF":2.1,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140175959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ethnic differences in pharmacogenomic variants: a south Asian perspective. 药物基因组变异的种族差异：南亚视角。
IF 2.1 4区 医学
Pharmacogenomics Pub Date : 2024-03-01 Epub Date: 2024-03-21 DOI: 10.2217/pgs-2024-0026
Bani Jolly, Vinod Scaria
{"title":"Ethnic differences in pharmacogenomic variants: a south Asian perspective.","authors":"Bani Jolly, Vinod Scaria","doi":"10.2217/pgs-2024-0026","DOIUrl":"10.2217/pgs-2024-0026","url":null,"abstract":"","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":" ","pages":"171-174"},"PeriodicalIF":2.1,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140175955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting RET mutation in medullary thyroid cancer. 针对甲状腺髓样癌的 RET 突变。
IF 2.1 4区 医学
Pharmacogenomics Pub Date : 2024-02-01 Epub Date: 2024-03-07 DOI: 10.2217/pgs-2023-0234
Tarek Assi, Zamzam Tikriti, Annoir Shayya, Rebecca Ibrahim
{"title":"Targeting RET mutation in medullary thyroid cancer.","authors":"Tarek Assi, Zamzam Tikriti, Annoir Shayya, Rebecca Ibrahim","doi":"10.2217/pgs-2023-0234","DOIUrl":"10.2217/pgs-2023-0234","url":null,"abstract":"","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":" ","pages":"113-115"},"PeriodicalIF":2.1,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140050118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Workforce readiness for pharmacogenomics and key elements for sustainment within the Veterans Health Administration. 退伍军人健康管理局内药物基因组学的人员准备情况和持续发展的关键因素。
IF 1.9 4区 医学
Pharmacogenomics Pub Date : 2024-02-01 Epub Date: 2024-03-05 DOI: 10.2217/pgs-2023-0193
Rebekah Ryanne Wu, Richelle Benevent, Nina R Sperber, Jill S Bates, Daniel Villa, Dilhan Weeraratne, Timothy A Burrell, Deepak Voora
{"title":"Workforce readiness for pharmacogenomics and key elements for sustainment within the Veterans Health Administration.","authors":"Rebekah Ryanne Wu, Richelle Benevent, Nina R Sperber, Jill S Bates, Daniel Villa, Dilhan Weeraratne, Timothy A Burrell, Deepak Voora","doi":"10.2217/pgs-2023-0193","DOIUrl":"10.2217/pgs-2023-0193","url":null,"abstract":"<p><p><b>Aim:</b> Understanding barriers and facilitators to pharmacogenomics (PGx) implementation and how to structure a clinical program with the Veterans Health Administration (VA). <b>Materials & methods:</b> Healthcare provider (HCP) survey at 20 VA facilities assessing PGx knowledge/acceptance and qualitative interviews to understand how best to design and sustain a national program. <b>Results:</b> 186 (12% response rate) surveyed believed PGx informs drug efficacy (74.7%) and adverse events (71.0%). Low confidence in knowledge (43.0%) and ability to implement (35.4-43.5%). 23 (60.5% response rate) interviewees supported a nationally program to oversee VA education, consultation and IT resources. Prescribing HCPs should be directing local activities. <b>Conclusion:</b> HCPs recognize PGx value but are not prepared to implement. Healthcare systems should build system-wide programs for implementation education and support.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":" ","pages":"133-145"},"PeriodicalIF":1.9,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10964838/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140028675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信